Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

NCT06908694 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of GLP1-receptor agonists in men with prostate cancer who are receiving androgen deprivation therapy.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · male only

Timeline Started 2025-07 · est. completion 2026-07

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT06908694 ↗

Description as written by the study sponsor.

GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.

Treatments tested

Semaglutide Pen Injector also known as Wegovy® Drug

The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.

Main thing measured	Number of Serious Adverse Events
Sponsor	Hamilton Health Sciences Corporation
Conditions studied	Prostate Cancer
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06908694 ↗